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Abstract 
 
DEVELOPMENT OF DUAL-PATHWAY INHIBITORS OF Raf/MEK/ERK AND 
PI3K/AKT SIGNALING PATHWAYS. 
 
By Sasha Fraser, B.Sc. 
 
 
A thesis submitted in partial fulfillment of the requirements for the degree of 
Master of Science at Virginia Commonwealth University. 
 
 
Virginia Commonwealth University, 2011.   
 
 
Major Director: Shijun Zhang, Ph. D., Medicinal Chemistry. 
 
 
In the present study, we designed a new chemical template that contains 
an oxindole moiety as potential dual-pathway inhibitors of the Raf/MEK/ERK and 
PI3K/Akt signaling pathways. The design hypothesis is to evaluate whether the 
oxindole ring system will approximately orient functional groups in a similar 
manner to the thiazolidinedione moiety, and thus maintain biological activity as 
dual-pathway inhibitors of the Raf/MEK/ERK and PI3K/Akt signaling pathways. 
Furthermore, the oxindole ring will provide the flexibility to allow the introduction 
of various substituents on the oxindole moiety, thereby facilitating 
comprehensive SAR studies to further explore the biological activity. 
 The oxindole analogs were biologically characterized by employing human 
leukemia U937 cells. Anti-proliferation activity using the 3-[4, 5-dimethylthiazol-2-
yl]-2, 5-diphenyltetrazolium (MTT) assay was tested, and all of the designed 
2 
compounds exhibited activity against the growth of U937 cells with micromolar 
potency. Notably, compared to lead compound 1, the oxindole analogs, exhibited 
improved anti-proliferation activity (4-fold increase). Western blot analysis 
revealed that the expression of critical components of the pathways such as p-
ERK and p-Akt, were consistently suppressed by these oxindole analogs, thus 
correlating the inhibition of the two signaling pathways with the anti-proliferative 
activity. The apoptotic effects of the most potent oxindole compounds were 
evaluated using flow cytometry to obtain preliminary mechanistic information. 
The results demonstrated that the compounds induced significant early- and late-
stage apoptosis. 
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1. Literature Review  
 Signal transduction pathways have long been recognized for their central 
role in the regulation of mammalian cellular programs in response to extracellular 
cues. As it pertains to the fine-tuning of important survival functions including cell 
cycle progression, apoptosis, and protein synthesis and growth, it is well 
documented that the Raf/MEK/extracellular signal-regulated kinase (ERK) and 
the phosphatidylinositol 3-kinase (PI3K)/Akt transduction pathways are among 
the key players. 1,2 
Notably, initial seminal studies have shown that mutations can occur at 
genes encoding for some of these pathway components, as well as at upstream 
molecules that transmit their signal through the pathways.1,3 Several reports have 
correlated the aberrations with the induction of malignant phenotypes. Currently, 
it is estimated that the pathways account for more than 30% all human cancer, 
most often in haematopoietic malignancies. 4 Given the high frequency of 
deregulation, the pathways have been considered key targets for therapeutic 
intervention and, a diverse range of small molecules have been developed to the 
target key nodes unique to the Raf/MEK/ERK and PI3K/Akt pathways.5,6 This has 
created a platform for a more selective targeted approach to cancer 
chemotherapy,  a  shift from the existing anti-mitotic cancer agents that crudely 
interfere with the basic machinery of DNA synthesis and cell division such as 
taxol and vinblastine.  
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1.1 Oncogenic Signaling 
The dependence of transformed cells on the signaling pathways has been 
extensively investigated. As summarized by Hanahan and Weinberg, the current 
concensus is that a fully malignant invasive tumor requires deregulation of at 
least six physiological processes which confers:7 
 
x Acquired self-sufficiency and independence of growth signals 
x Insensitivity to growth inhibitor signals  
x Circumvention of programmed cell death 
x Limitless replicative potential and telomere erosion 
x Sustained angiogenesis for nutrient supply 
x Invasion and Metastasis 
 
Figure 1: Simplified representation of the increased cell proliferation and cancer cell 
survival 
 
Abnormalities in the Raf/MEK/ERK and the PI3K/Akt pathways impinge on 
all of these processes directly or indirectly. Generally, the constraints placed on 
proliferative response by the pathways are perturbed. In addition to intrinsic point 
mutations of signal transducer molecule such as Ras, the abnormalities include 
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activating mutations of RTK and chromosomal translocation, as well as over-
expression of normal gene products. Although, cancers are diverse with multiple 
possible combinations of defects; in most cases, deregulated signaling provide 
the basal platform for neoplastic progression (Figure 1).3 As in the case of the 
erosion of telomeres, although it is one of the six hallmarks of cancer, it is a 
result of repeated cell division. Further mutations are essentially for additional 
growth advantage for progeny. Angiogenesis allows development of nurturing 
vasculature from blood vessels of adjacent cells. The acquired self-reliance 
enables cell to colonize distant cells, most frequently bone and lymph node in a 
process termed metastasis. Due to the direct connect between uncontrolled 
growth and the latter complication usually leading to death; growth inhibition, cell 
cycle arrest and apoptosis of transformed cells is the desired endpoint of anti-
cancer agents.8 
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1.2 The Raf/MEK/ERK Pathway 
 
The Raf/MEK/ERK pathway is the prototypic pathway of the evolutionary 
conserved family of mitogen-DFWLYDWHG SURWHLQ NLQDVHV 0$3.¶s. It couples 
signals from many receptors, both membrane bound (e.g. receptor tyrosine 
kinases) and intracellular tyrosine kinases (e.g. ABL), to transcription factors 
which serve as the terminal effectors in the modulation of gene expression 
(Figure 2). 1,4 
 
 
 
Figure  2: Schematic diagram of the activation of the Raf/ MEK/ ERK pathway and its 
downstream targets. 
 
Historically, the Raf/MEK/ERK pathway has been synonymous with cell 
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cycle progression, but more recently pathway has been associated with the 
phosphorylation of several proteins involved in apoptosis. The core module of the 
pathway is three tiered and consists:  Raf, a MAPK kinase kinase (MAPKKK) that 
can phosphorylate and activate MEK, a MAPK kinase (MAPKK), which in turn 
phosphorylate and activate ERK, a MAPK.9 Growth factors are largely 
responsible for pathway stimulation. However, the pathway can be activated to 
some extent by ligands for heterotrimeric G protein-coupled receptors (GPCRs) 
and cytokines among other stimuli. The ligand-mediated activation via receptor 
tyrosine kinases triggers the formation of Ras in its GTP bound conformation. 
Subsequently, stimulating the translocation of Raf the cell membrane. 
Aberrant activation of this pathway is a common occurrence. Importantly, 
core modules 5DVDQG5DIZHUH ILUVW GLVFRYHUHG LQ WKH¶VDV WUDQVIRUPLQJ
oncogenes of the murine sarcoma virus.10 This landmark finding of the cellular 
origin of retroviral oncogene has contributed greatly to delineating molecular 
changes that drive tumorigenesis. The seminal link between the pathways and 
human cancers has been substantiated by 25 years of research. Several 
oncogenes were later found. For example, c-sis oncogene which encodes 
platelet-derived growth factor (PDGF), as well as oncogenes that encodes 
constitutively active growth factor receptor tyrosine kinases (RTKs), for example, 
v-erb for the epidermal growth factor receptor (EGFR) and non-receptor tyrosine 
kinases, for example, ABL, that relay signals through the ubiquitous Raf/ MEK/ 
ERK pathway. 10 
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1.2.1 Receptor Tyrosine Kinase (RTK) 
The membrane-spanning receptors of the RTK family constitute a ligand- 
binding domain, a single trans-membrane domain and an intracellular domain 
with tyrosine kinase activity.11 The cytoplasmic domain contains a conserved PTK 
domain that is subject to phosphorylation. A major requirement for signaling 
mediated by RTKs is ligand-induced dimerization of receptors that result in the 
autophosphorylation of the receptor subunits.  These auto-phosphorylation sites 
serve to recognize the src homology 2 (SH2) of a variety of signaling proteins. 
One such protein is the adaptor growth factor receptor-bound protein 2 (Grb2). 
The second binding domain of the adaptor molecule, SH3, allows it to associate 
with the guanine nucleotide exchange factor (GEF), son-of-sevenless (SOS), 
which catalyze GDP release and GTP binding which activates Ras. 12 
As the first RTK to be discovered, the EFGR also known as ErbB1 
homologous to the v-erb-B transforming protein of avian retrovirus is generally 
used as a RTK model. The EGF signal is terminated primarily through 
endocytosis of the receptor-ligand complex. There are various alterations that 
interfere with ErbB receptors functions that contribute to human cancers. 
Mutations are often found in the intracellular domain which affects tyrosine 
kinase activity and abrogates the requirement for growth factor signals. In some 
tumors, increased production of EGF-related growth factors leads to the 
persistent activation of ErbB receptors. Similarly, over-expression of receptor, 
and oligerimerization mimics of EFGR and other RTKs have been implicated in 
numerous cancers including ovarian and gastric carcinomas and glioblastoma. 13  
9 
1.2.2 Non-Receptor tyrosine kinase 
 The non-receptor kinases are key elements of intracellular signaling 
induced by extracellular stimuli, such as cytokines and growth factors.These 
proteins are localized both in the nucleus and cytoplasm, and regulate cell 
growth, survival and morphogenesis via the PI3K/Akt and the Raf/MEK/ERK 
pathways. The family of Abelson murine leukemia virus (c-Abl) tyrosine kinase 
has gained much interest since the finding that a single molecular abnormality 
can cause transformation of a hematopoietic progenitor into a malignant clone. 
Similar to its receptor counterpart, c-Abl was originally identified as the cellular 
homolog of the v-Abl oncogene of the Abelson murine leukemia virus, and its 
function depends on its kinase activity, which is believed to involve 
phosphorylation of Tyr245 and Tyr412. 14 
Abnormality of the Abl protein through the reciprocal translocation 
between the ABL chromosome 9 and chromosome 22 near a locus termed the 
break-point cluster region (BCR) is the primary mode of deregulation in CML. 
The result is a constitutively active ABL tyrosine kinase domain which abrogates 
the need for activation by other cellular messaging proteins. This BCR-ABL 
transcript, also called the Philadelphia chromosome (Ph+) accounts for more than 
95% of hematopoeic malignancies. 15 Interestingly, in the stable or chronic phase 
of CML while there is a massive increase in the number of white blood cells, their 
maturation and function of the white blood cells are normal until a malignant 
clone loses its ability to differentiate resulting in disease progression to highly 
refractory leukemia.  
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1.2.3 Ras 
Ras is a notable member of the GTPase superfamily (also known as 
guanine nucleotide binding protreins), and it is a critical link that allows signal 
transduction from the tyrosine kinases. Three isoforms have been identified (H-
Ras, N-Ras and K-Ras). These proteins are typically anchored on the 
cytoplasmic face of plasma membrane by farnesylation, where they cycle 
between GTP-bound and GDP-bound state acting as a binary switch for several 
signaling pathways including the Raf/MEK/ERK and the PI3K/Akt pathways. It 
has been shown that there is specificity in the capability of isoforms to activate 
the pathways; K-ras preferentially activates the Raf/MEK/ERK pathway whereas 
K-Ras activates the PI3K/ Akt pathway.9 
 Localisation at the cell membrane allows the Ras proteins to be positively 
regulated by guanine nucleotide exchange factor such as SOS which promotes 
GDP dissociation. Consequently, the nucleotide free binding pocket will bind 
GTP since its concentration in the cytosol is ten-folds higher than that of GDP, 
markedly changing the conformation of the switch 1 and switch 2.  16 
Figure  3: The sites of mutations detected in Ras are indicated. These mutations at (12, 
13, 59, 61, 63) locks the Ras protein in an active state, which cannot be inactivated by 
the GTPase. 
 
11 
Damage to these small GTPases switches can have catastrophic effects. 
The Ras mutants are ranked among the most potent transforming proteins 
known, accounting for 30% of all cancers, with pancreas (90%), thyroid (60%) 
and colon cancer (50%) having the highest prevalence. 17 The activation of the 
mutant Ras genes is invariably by point mutation at the codons: 12, 13, 59, 61 
and 63 (Figure 3). 18,19 These activating mutations stabalize the GTP-bound state 
and impair the GTPase activity of Ras, locking the Ras protein into its active 
conformation. Within the ERK signaling pathway, active Ras binds the effector 
Raf kinase, stimulating their translocation to the cell membrane, where Raf 
activation takes place.  
 
1.2.4 Raf 
The Raf serine/ threonine kinases lie at the apex of the Raf/MEK/ERK 
pathway module, and exist as the isoforms: A-Raf, B-Raf, and Raf1. These 
proteins have three functional domains: CR1, CR2 and CR3 (Figure 4). The CR1 
domain is necessary for Ras binding and activation. The CR2 domain is the 
regulatory domain, and the CR3 is the kinase domain. Although these isoforms 
share several structural features they exhibit non-redundant functions and differ 
considerably in their modes of regulation.7,19 
The recruitment to the cell membrane by GTP-bound Ras is the initiating 
event and full activation of Raf-1 follows a complex sequence of (1) 
phosphorylations/ dephosphorylations, (2) protein-protein interactions, and (3) 
lipid/ protein interactions. 17 These events enhance the catalytic activity of Raf1 
12 
by both facilitating the activation of the kinase domain and neutralizing auto-
inhibitory molecules. The auto-inhibitory conformation state is maintained by 14-
3-3 dimers, and relief from auto-inhibitory molecule entails dephosphorylation at 
S259 by the serine threonine phosphatases (PP2A). This allows Raf-1 to assume 
a new conformation in which it can be phosphorylated at S338, and activated by 
kinases including P21 activated protein kinases (PAK).  20 
The S259 and S338 sites of Raf-1 are conserved in A-Raf which follows a 
similar activation patterns to Raf-1. However, B-Raf has two aspartate residues 
at the position equivalent to S338 making the protein constitutively active due to 
the negative charge of the aspartate. As a result B-Raf can be sufficiently 
activated by Ras only, while Raf 1 requires other factors. 
 
Figure  4: The sites of mutations detected in the B-Raf protein are presented. In all, 90% 
of B-Raf mutations in melanoma involve V599. Mutations at S364, S428 and T439 
insulate connectivity to the PI3K/ Akt pathway. 
 
B- Raf is the most oncogenic isoform. B- Raf mutations have been reported in 
66% of melanoma, 53 % of thyroid cancer and 30% of ovarian cancer.5 The 
activating mutations within the kinase domain are the most aggressive, and often 
converts Val599 to Glu. Interestingly, B-Raf mutations confer low kinase activity. 
The recent discovery that B-Raf can form heterodimers with Raf-1 is a point of 
13 
high interest. Recently, it has been shown that B-Raf can activate Raf-1. The 
kinase activity of the B-Raf/ Raf-1 heterodimer is considerably higher than the 
ability of either B-Raf or Raf-1 as independent entities. It is believed that 
heterodimerization between B-Raf and Raf-1 proteins may allow the impaired B-
Raf to activate Raf-1. 21 
 
1.2.5 Mitogen-activated Protein/Extracellular Signal-regulated Kinase (MEK) 
MEK proteins are the most relevant target of Raf. This family of dual-
specificity kinases has both S/T and Y kinase activity. Their structure constitutes 
a regulatory domain and a MAP kinase-binding domain necessary for binding 
and activation of ERKs. Surprisingly, there has been no identified oncogene 
derived from MEK. MEK also differ from the upstream molecules Ras and Raf in 
that it has relatively few phosphorylation sites.  
0(.¶V DFWLYLW\ LV SRVLWLYHO\ UHJXODWHG E\ 5DI NLQDVH WKURXJK
phosphorylation at Ser 218 and serine 222. 21 MEK can be partially activated by 
phosphorylation at either site. There are several featured MEK inhibitors that 
block ERK activity by a noncompetitive mechanism, by binding in a pocket 
adjacent to but not overlapping the ATP binding site. While this feature is 
desirable, the demise of the MEK inhibitors is the high frequency of crosstalks 
upstream MEK that can circumvents signaling beyond MEK.  
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1.2.6 Extracellular signal-regulated kinases (ERK) 
The main physiological substrates of MEK are the ERK family of serine/ 
threonine and tyrosine kinases of the Raf/MEK/ERK pathway, expressed in all 
mammalian tissue, with ERK2 levels generally higher than ERK1.  Dual 
phosphorylation activates both at T202/Y204 for ERK 1 and for T185/Y187 ERK2 
in humans within a conserved Thr-Glu-Tyr (TEY) motif in their activation loop.  
Unlike MEK, ERK activation requires phosphorylation at both sites for full activity, 
and Tyr phosphorylation has been shown to precede Thr phosphorylation.22  
 Both nuclear and cytoplasmic have been identified for ERK. Activated Erk 
can phosphoylate cytoplasmic signaling proteins including P90 ribosomal S6 
kinase (RSK). ERK can also translocate to the nucleus, where it directly 
phosphorylates member of the TCF family, for example Elk-1. TCF activate 
numerous immediate early genes (IEG) including c-fos and c-myc that binds the 
promoter of many genes. Accordingly, phosphorylation of TCF potentiates the 
ability of IEG products to modulate the expression of many other genes including 
cyclin D1; thereby, facilitating G1/S transition in the cell cycle. 4, 23 
 To date, over 160 substrates have identified. 24The apparent specificity and 
efficiency within the MAPK signaling is partly achieved through docking motifs, 
namely, the D, DEF, CD, and ED domains which are present in scaffolding 
proteins such as KSR. While the D domains are recognized generally by the 
family of MAPKs, the second domain termed DEF (docking site for ERK and 
FXFP), that consists of the Phe-Xaa-Phe-Pro sequence has been reported to be 
recognized only by ERK1/2 in the C-terminal of the phosphoacceptor site. Also at 
15 
the C-terminal is the conserved common docking motif outside the catalytic 
domain which contains acidic and hydrophobic residues necessary for 
hydrophobic and electrostatic interaction with residues of the D-domain. Similar 
to the D motif, the ED motif is adjacent the catalytic center of Erk which is also 
believed to contribute to substrate binding specificity. 25 
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1.3 The PI3K/Akt Pathway  
Similar to ERK pathway, the engagement of several different growth 
factors with RTKs feed into the PI3K/ AKT pathway. The net effect is the 
inhibition of the apoptosis and stimulation cell cycle progression and cellular 
translation. Germane to survival signaling the class 1a PI3K kinases triggers the 
production of the second messenger phospatidylinisotol 3,4,5-triphosphate 
(PIP3). PIP3 activates central engine of the pathway, AKT, which in turn 
modulates several downstream signaling proteins (Figure 5). 20, 26, 27 
 
 
Figure 5: Schematic diagram of the activation of the PI3K pathway and a number of 
critical downstream targets. 
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One of the most important AKT substrate is mTOR which allow the 
pathway to mediate a key step in translational control. The classical thought was 
that the pathway discretely exerts anti-apoptotic effects through phosphorylation 
of critical targets including FOXO, BAD and caspases. However, recent studies 
also indicate that Akt also promotes cell cycle progression by its ability to 
phosphorylate MDM2 and GSK-3. Though, the connection between its role in 
apoptosis and cell cycle is not entirely clear p53 seem to be involved. 1 
Insult to the PI3K/ AKT pathway has been implicated tumorigenesis. The 
importance of PI3Ks in cancer was confirmed by the discovery that the PI3K 
catalytic subunit alpha-isRIRUP JHQH 3,.&$ ZKLFK HQFRGHV SĮ 2WKHU
defects in the pathway may include AKT are overexpression, and the negative 
regulators of the pathway such as the tumor suppressor, PTEN may be mutated 
or absent. 28,29 
 
1.3.1 Phosphoinisitol Kinase (PI3K) 
The PI3K proteins are a family of lipid kinases that serve to phosphorylate 
the 3-hydroxy group of phospoinisitol. These PI3K proteins are cytoplasmic 
heterodimers composed of a one of several p110 catalytic subunits, such as 
PIK3Ca and PIK3Cb, and a regulatory p85 protein. The RTKs can activate the 
PI3K pathways by two mechanisms. This may be directly through the binding of 
the SH2 domain of p85 regulatory subunit of PI3K to specific phosphotyrosine 
residue of the activated RTK.30 Alternatively, RTK may bind the adaptor proteins 
which activate Ras inducible membrane translocation and activation of p110 
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catalytic unit of PI3K.31 The activated PI3K phosphorylates phoshatidylinositol-
3,4-bisphosphate (PIP2) to generate the secondary phoshatidylinositol-3,4,5-
triphosphate (PIP3). Subsequent signaling from the PI3k Ia is mediated primarily 
through the recruitment of protein containing PH domain including PDK1 and 
$.7WRWKH¶SKRVSKRLQRVLWLGHV The membrane bound phospholipid, PIP3, acts 
as a docking site to bring the Akt from the cytosol to the plasma membrane in 
closer proximity to (PDK1) poised for activation.  
The contribution of PI3Ks to cancer progression was confirmed by the 
discovery of the mutated PI3K catalytic subunit, alpha-isoform gene (PIK3CA), 
which HQFRGHV SĮ 7KUHH RI WKHPRVW IUHTXHQW 3,.&$PXWDWLRQV (.
E545K in the helical domain incur a charge reversal that inhibits electrostatic 
interactions between the inserted amino acids and R340 and K379 on the SH2 
GRPDLQRIUHJXODWRU\SĮ)LJXUH 6). H1047R in the kinase domain, have been 
shown to increase PIP3 levels. It has been proposed that R forms a hydrogen 
ERQG ZLWK / RI SĮ ZKLFK LQ WXUQ OHDGV WR FDWDO\WLF DFWLYLW\ RI SĮ 32 
Cumulatively, studies indicate that the gain of function in helical domain 
mutations is independent of binding to the regulatory p85 but requires binding to 
RAS-GTP. In contrast, the kinase domain mutation is active in the absence of 
RAS-GTP binding but is highly dependent on the interaction with p85. Colorectal, 
brain and gastric cancers are reported to have a high rate of PIK3CA gene 
mutation with frequencies of 32%, 27% and 25%, respectively. 29 
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Figure 6: Mutations of the PIK3CA gene of the catalytic p110 domain in the helical 
domain: E542K and E543 K, and in the catalytic domain H1047. 
 
1.3.2 Akt  
The AKT/ PKB serine/ threonine kinases are the principal target of the 
PI3K pathway. Similiar to Ras, Akt was discovered as the cellular gene of the 
transforming retrovirus AKT8  which exhibited kinase properties similar to protein 
kinases A and C. It is expressed in three isoforms: Akt1, Akt2, and Akt3, all of 
which possess an N-terminal pleckstrin homology (PH) domain involved in lipid 
binding, a kinase domain and a regulatory C-terminal tail. Akt is activated via 
phosphorylation of two residues: T308 and S473.33 PIP3 facilitates the 
phosphorylation of AKT at T308. An additional phosphorylation in the C-terminal 
at S473 is also required for full activation, and the mammalian target of 
Rapamycin 2 (mTOR 2) complex is believed to have some role, but the precise 
mechanism remains controversial. 
Activated Akt phosphorylates and stimulates many survival factors. It 
promotes protein synthesis and growth by activating mTOR1 through effects on 
the intermediary tuberous sclerosis (TSC) 1/2 complex. Akt influences apoptosis 
by phosphorylating molecules such as BAD and BIM. Moreover, Akt can 
modulate cell cycle progression via regulation of GSK-3 and MDM2 activity which 
20 
regulates cyclin D and myc. 1  A recent report identified a somatic mutation in the 
PH domain of AKT1 (E17K) in 8% of breast cancers. The acidic Glu 17 typically 
forms an ionic interaction with basic Lys 14 in the pocket however, in the case of 
the Lys 17 substitution in E17K, the positively charged Lys 17 can no longer 
interact with Lys 14. Consequently, the mutated AKT1 product is recruited 
to the membrane through a PI3K-independent mechanism. 1, 34 
 
1.3.3 Mammalian Target of Rapamycin 2 (mTOR)  
Integral to the translation of cell growth proteins in mammals is the murine 
target of rapamycin mTOR, a multidomain serine/ threonine kinases known to be 
inhibited by the drug rapamycin. As the downstream target of Akt, mTOR is 
activated by Akt-induced phosphorylation of the intermediary tuberous sclerosis 
complex2 (TSC2). The main function of mTOR is the regulation of translation, 
particularly the recruitment of ribosomes to mRNA. Several survival proteins 
SRVVHVVLQJDWHUWLDU\VWUXFWXUHZLWKSRO\S\ULPLGLQHVWUHWFKLQWKHLU¶XQWUDQVODWHG
region (UTR) are difficult to translate, and relies on mTOR for efficient translation. 
7KLV UHTXLUHV WKHDVVHPEO\ RI D WUDQVODWLRQDO FRPSOH[ WKDWDWWDFKHV WR ¶875
The translation complex comprises eIF4E which recognize the cap structure at 
WKH¶HQGRIP51$51$KHOLFDVHH,)$DQG its activator eIF4B which serves to 
XQZLQG WKH¶875 structure, all of which collaborates to allow the 40S ribosomal 
subunit binding. 1,35 
The activation of mTOR requires the association with Ras homologue 
enriched in brain (Rheb) in its GTP form. The tuber schlerosis complex (TSC 1 
/2) is the key integrator of PI3K/ mTOR signaling, and acts by promoting Rheb 
21 
GTPase activity which negatively regulate mTOR activation. However, TSC1/2 is 
inhibited by PI3K signaling. The activated mTOR complex exerts its effect 
through phosphorylation of ribosomal p70S6 kinase (S6K1) and the eukaryotic 
initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1). 1 4E-BP1 is known to 
LQKLELW¶FDS-dependent mRNA. The phosphorylation of 4E-BP1 releases eIf4E to 
facilitate the mRNA binding to the rhibosome and translation initiation. The 
phosphorylation of 4E-BP and the free eIf-4E generally stimulate two-fold 
increase in translation. However the translation of specific protein such as c-myc 
containing high structured UTR can be significantly larger.  S6K1, in a more 
indirect manner acts on many substrate including RNA helicase and other 
substrates involved in translation. Both substrates stimulate the translation of 
proteins necessary for cell growth and division of protein such as c-myc and 
cyclin D. 35 
 
1.3.4 Phosphatase and Tensin homolog deleted on chromosome 10 (PTEN) 
The PI3K pathway is negatively regulated by the tumor suppressor protein 
phosphatase and tensin homolog deleted on chromosome 10 (PTEN). The lipid 
phosphatase serves to check and maintain balance between PIP2 and PIP3 by 
degradation of PIP3 through the removal of the phosphate group from the 3' 
position of the inositol ring. PTEN is ranked among the most common mutated 
tumor suppressors in human cancers, second only to p53 mutations. The 
immediate consequence of loss of function is increased levels of PIP3 and up 
regulation of a number of AKT regulated proteins. 36   
22 
1.4 The Raf/MEK/ERK, the PI3K/Akt Pathways and Apoptosis  
 
 
The Raf/MEK/ERK cascade and the PI3K/Akt cascade have been 
demonstrated to control the activity of several proteins involved in apoptosis. Of 
the two modes of apoptotic regulation, designated as receptor mediated and the 
mitochondrial mediated, the mitochondrial mode is thought to be the principal 
target of survival signaling pathways. The Bcl-2 protein family is largely 
responsible for this mode of regulation. The BH3-only members including Bad 
and Bim, are essential initiators of apoptosis activated in response to distinct 
cytotoxic and developemental signals. They selectively bind to pro-survival 
members of the Bcl-2 family such as Bcl-2, Bcl-xL to trigger the mitochondrial 
release of cytochrome c by a mechanism requiring their pro-apoptotic relatives 
Bax or Bak (Figure 7).  It is believed that the balance of the antiapoptotic proteins 
and the pro-apoptotic proteins dictates cell survival or apoptosis. 13, 37 
The BH3-only protein (B-Cell CLL/ lymphoma 2 (Bcl-2)/ Basal cell 
lymphoma-extralarge (Bcl-xL) associated promoter (BAD) was the first pro-
apoptotic Bcl-2 family member found to be regulated by extracellular survival 
sinaling. In cells stimulated with mitogens, such as EGF, Bad is phosphorylated 
at S136 by AKT. Several other reports indicate that RSK and S6K can both 
phosphorylate BAD at S112.38 These phosphorylation events on apoptotic 
regulatory molecules affect their stability, and alter their subcellular distribution.  
Input from both pathways inhibits the pro-apoptotic activity of BAD by allowing 
recognition by, and subsequent interaction with the 14-3-3 scaffold protein in the 
cytosol. The BAD-14-3-3 heterodimer promotes cell survival by sequestration of 
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BAD in the cytosol where it is spatially separate from the mitochondria and pro-
apoptotic members of the Bcl-2 family. Conversely, upon withdrawal of mitogens, 
hypohosphorylated BAD induce oligerimerization of Bak and Bax. Activated 
BAX/BAK dimer induces mitochondrial outer membrane permeabilization 
(MOMP) release as cytochrome c from the mitochondrial intermembrane space 
(IMS) to the cytosol where it binds protease-activating factor 1 (APAF1). 
Thereby, forming a structure termed the apoptosome that recruits and activates 
effector caspases such as caspase 9 which cleave and activate downstream 
caspases, caspase 3 and 7, that participate in the execution of apoptosis. 37,39 
 
Figure  7:   Interaction with Bad in the unphosphorylated state associates with Bcl-2 or 
Bcl-XL to promote apoptosis. Akt and ERK phosphorylates Bad on S136 and S112 
respectively. These phosphorylation events cause Bad to associate with 14-3-3 proteins, 
thus inhibiting apoptosis.  
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A second BH3-only protein Bim, which has a major role in the death of 
haematopoietic cells is also regulated by the two pathways. Akt can directly 
phosphorylate Bim at S87 to promote binding to 14-3-3 proteins and inhibit its 
proapoptotic activity. ERK phosphorylation of Bim on S69 can result in 
ubiquitination of Bim and subsequent proteosomal degradation. In contrast to 
BAD, Bim is also modulated at transcriptional level. 40 Reports indicate that the 
pathways can cooperatively regulate the gene expression of Bim via the 
transcription factor, Foxo-3a. AKT and SGK can phosphorylate FOXO3A at 
Thr32, Ser253 and Ser315. Similar to post-transcriptional level, the 14-3-3 
proteins bind the phosphorylated sites and sequester FOXOs in the cytosol, 
thereby abrogating their ability to enter the nucleus and activate quiescent, 
apoptotic genes expression. ERK phosphorylates FOXO3A at Ser294, Ser344 
and Ser425, which increases FOXO3A interaction with the E3-ubiquitin ligase 
MDM2, thereby directing proteasomal degradation of FOXO3a. 38 
The pathways also enhance the translation of several weak mRNA that 
are often involved in apoptosis for example, Mcl-1. Such proteins possess tertiary 
structures that are difficult to translate and require the assembly of a translation 
FRPSOH[ZKLFKDWWDFKHVWRWKH¶8757KHWZRSDWKZD\VFRQWUROWKHDVVHPEO\RI
the eIF4E translation apparatus. ERK, p90 RSK1 and p70SK6 are a few 
intermediatory molecules involved in the regulation of weak mRNA translation. In 
some cases, the two pathways will phosphorylate the same molecule in the 
translation complex such rhibosomal protein S6 (rpS6). 1, 40 
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Recently it has been shown that the Raf/MEK/ERK cascade can 
phosphorylate the terminal effector molecule, caspase 9 on residue T125 which 
contributes to the inactivation of this protein. 41 Interestingly, caspase 9 is also 
phosphorylated by the Akt. The significance of the caspase 9 phosphorylation by 
Akt is arguable, as this phosphorylation site is not evolutionally conserved. 
However, cumulatively Raf/MEK/ERK and PI3K/Akt pathways appear to engage 
in intimate crosstalk to regulate the survival status of dividing cells.  
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1.5 The Raf/MEK/ERK, the PI3K/Akt Pathways and Cell Cycle 
 
Cell cycle regulation is bi-modal requiring signal from both the  Raf/MEK/ 
ERK and the PI3K/Akt pathways. 42 In mammals, all cells with the exception of 
liver and muscle rely on these pathways throughout their lifetime, for both 
development, and maintenance and repair. In a normal cell, the cell cycle is an 
orderly progression through four distinct phases Go/ G1, S, M, G2. In the S 
(Synthesis) phase, the cell duplicates its DNA and in the M (Mitotic) phase, the 
DNA is distributed equally between the two daughter cells. These two phases are 
separated by the two gap phases Go/G1 and G2.  
To ensure coordination, there is a restriction point at Go/G1 and two 
additional checkpoints at the G1/S and G2/M. The core proteins involved in the 
regulation of these checkpoints are the cyclins and the cyclins dependent 
kinases. 42These cyclin/ cdk complexes are formed during the different phases. 
The concentration of the cyclins are regulated by signaling, while the Cdks 
concentration stays the same throughout the cell cycle and whilst their activity is 
regulated in response to changes in cyclin concentration. 
Present evidence indicates that CDK 4 and CDK 6 associate mainly with 
cyclin D in the regulation of G1. CDK1 associate with cyclin B to regulate G2/M 
transition, while CDK 2 is involved in the regulation of the G1/S transition and 
DNA synthesis by its association with cyclin E and cyclin A (Figure 8). 43 Cyclin D 
is one of its most cited transcriptional targets of the relevant to cell cycle, a major 
requirement for passage through the G1 restriction point and commitment to the 
cell cycle. Sufficient accumulation of Myc is necessary for the activation of Cyclin 
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D expression, which subsequently associate with cyclin dependent kinases, 
phosphorylate Rb, release E2F and promote DNA synthesis. 42,44 
 
Figure  8: Erk and Akt stimulate cyclin D expression, and the association of cyclin D with 
CDK causes phosphorylation of Rb. In the phosphorylated state Rb release the E2F 
transcription factor promote  DNA synthesis and progression through the phases. 
The dynamic control of Myc by sequential phosphoylation allows Myc to 
integrate upstream signals from Erk and AKT. It can be substantially stabilized 
when phosphorylated at Ser62 by Erk activity. Subsequent phosphorylation of 
Myc at Thr58 by Gsk3, however, initiates a destabilization process in a 
sequential manner. Interestingly, phosphorylation at Thr58 requires prior 
phosphorylation at Ser62. 38, 42, 45 Hence, as Ras activity declines, Gsk3b cease 
the opportunity to initiates phosphorylation of Myc at Thr58 and triggers 
degradation.  
By inactivating GSK-B, PI3K pathway blocks Myc degradation. There has 
been report of the pathways cooperatively increases cyclin D mRNA levels 
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increase of up to 20 fold, which generally peaks after 6 hours of mitogen 
stimulation. 45 In addition to inducing the transcriptional activation of cyclin D1 
and D2, Ras signaling also stimulate the phosphatase Cdc25A that removes the 
negative regulatory phosphates from the Cdk. The myc transcription factor 
functions as a heterodimer with its obligate counterpart Max.  The related protein 
Mad1 competes with Max. The myc/ max heterodimer positively regulate 
transcription whereas the myc/ mad1 represses transcription. Studies also 
indicate convergence of both pathways via RSK and S6K phosphorylate Mad1 
on Ser 145. Thus, promoting Mad1 degradation, myc/max dimerization and 
induction of growth genes not exclusive to cyclin D. 46 
Careful dissection has revealed that while sustained ERK1/2 activation is 
required until the late G1 phase for successful entry into the S-phase, the 
accumulation of PI3K products is necessary for the late G1 progression.9 
Evidence shows that the stimulation of quiescent cells (Go) cause two peaks of 
activation. The first peak due to Raf/ MEK/ ERK activation and subsequent entry 
into the G1, and the second at mid-G1 phase the PI3K pathway peak. Several 
studies also suggest activation of the pathways in late S that persist until the end 
of mitosis. Present evidence indicates that their mechanisms of regulation differ 
during G2/M checkpoint. The inhibition of the PI3K pathway interferes with mitotic 
entry by cdc25 activation and increase cyclin B1 expression, whereas inhibiting 
the ERK pathway interferes with mitotic entry but has little effect on cdc25 
activation and cyclin B1. 47 
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1.6 Signaling Dynamics 
The Raf/MEK/ERk and PI3K/Akt pathways are driven by phosphorylation 
and de-phosphorylation reactions mediated by specific kinases, phosphatases, 
adaptor proteins and scaffolding proteins. The balance between these signals 
may widely vary in different tumors, and are important for sensitivity and outcome 
of drug therapy. However, the protein kinases have rapidly become one of the 
most pursued protein sub-family in the quest for novel drugs. Several compounds 
have been credited with putative chemotherapeutic activity. The majority of these 
inhibitors target various conformations of ATP, which often result in compounds 
exhibiting multiple kinase targets. Besides, in 2001 Imatinib (Gleevec) became 
the first therapeutic agent of a target molecule to enter clinical use. Imatinib acts 
by blockade of the non-receptor tyrosine protein kinase BCR-ABL.48,49 Aberrant 
signaling by these chimeric proteins is rather similar to signaling activated by 
membrane bound receptor tyrosine kinase (RTK). The success of Gleevec has 
been the long-standing proof of concept for targeting the Raf/MEK/ERK and the 
PI3K/ Akt pathways.     
The intrinsic mutations featured in the Raf/MEK/ERK are principally at Ras 
and Raf.14 While several inhibitors have been developed to intercept oncogenic 
signaling, the Raf and MEK inhibitors remain the most attractive target of the Raf/ 
MEK/ ERK pathway. To date, pluripotent Raf inhibitor, Sorafenib (BAY43-9006) 
and the allosteric and highly selective MEK1/2 inhibitors, Sulumetenib (AZD6244) 
and PD0325901 are the best explored inhibitors of the Raf/MEK/ERK pathway.  
Sorafenib targets Raf, PDGFR and VEGFR, and was approved for the treatment 
30 
of advanced renal cancer.50,51 CI-1040, the first MEK inhibitor to enter clinical 
trials, and its second generation inhibitors PD0325901 were well tolerated by 
patients but showed insufficient anti-tumor activity to warrant further 
developement. Similiarly, a second MEK inhibitor AZD6244 was terminated as a 
mono-therapy drug candidate in late phase trials in patients with melanoma, and 
it is currently in clinical trials for combination therapy. 52 
As for the PI3K/Akt pathway, mutations are most frequently reported at 
Akt, PTEN and PI3K. Within the PI3K/PTEN/Akt pathway, the main therapeutic 
targets: PI3K, mTOR and Akt (also referred to as PKB). In the PI3K pathway the 
second generation rapamycin analogs with improved pharmacological properties 
show productive therapeutic outcomes. The best evidence is the treatment of 
advanced renal cancer with tersirolimus, a rapamycin prodrug that has been FDA 
approved. 53 Others include the water soluble rapamycin (CCI-779) in phase III of 
development, and the two other agents, (RAD001) and (AP23573) in earlier 
phases of development. The PI3K inhibitors have been less successful. 
LY294002 and wortmannin, two well-known PI3K inhibitors, were shown to have 
effective anti-tumor activity, but had limited clinical value due to poor 
pharmacokinetic properties. 54 Likewise, perifosine, the most developed AKT 
inhibitor has not been shown to be beneficial as a single agent in several phase II 
studies. 55 Regardless, the repertoire of well-characterized inhibitors should not 
be discounted based on grim rate of success, as they have contributed a wealth 
of information to targeted cancer research. 
While the small molecules inhibitors of the pathways are forecasted to 
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significantly impact the cancer chemotherapy, the underlying biochemical 
complexity remains a challenge. There exist several different layers of regulation 
which is heavily dependent on cell type, dosage and duration. Supporting studies 
indicate distinct differences in cell lines from same target tissue, although results 
from some in-vitro reports suggest similar mechanism from cell of differing origin. 
In a study by Kiyatkin this phenomenon was highlighted with MCF7 and T47D 
breast cancer cell lines. The T47D breast cancer cells displayed MEK resistance 
due to a PI3K/ AKT sensitive compensatory pathway, which was absent in the 
MCF7 breast cancer cell line which appear to signal predominantly through the 
MAPK pathway.56 
 There are also examples of dependence on dose and duration. In an 
elegant study by Haugh, ERK and PI3K -dependet Akt phosphorylation in PDGF-
stimulated NIH 3T3 fibroblasts were evaluated using different combinations of 
ligand dose and stimulation time. The results supported the notion that the extent 
of ERK inhibition depends strongly on both dose and duration. At short 
stimulation time, ERK activation was substantially effected by PI3K inhibition 
when stimulated by low but not high PDGF concentration. The effect of Ras 
inhibition was similar but ERK phosphorylation was less sensitive to PDGF 
concentration. 57 The observed stimulation conditions are believed to be subject 
to negative feedback loops, but a definitive pattern is yet to emerge. 
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2.  Crosstalk  of  the  Raf/MEK/ERK  and  PI3K/Akt  Signaling  Pathways  
The cosstalk between the two pathways is undisputed, and suggest high 
intimacy between the regulation of cell cycle and apoptosis (Figure 9). The 
transcription factors, Myc and E2F exist at the core of this interface. Myc 
activates E2F which promotes the transition of phase G1 to S the cell cycle. 
58Overexpression of E2F stimulates the expression of tumor suppressor, ARF, 
which inhibits the activity of MDM2. It is believed that the MDM2, an E3 ubiquitin 
ligase, targets p53 and accelerates its proteolytic degradation and maintains p53 
at a low level. 43 Thus, by inhibiting MDM2, ARF prevents p53 degradation and 
consequent stabilization. This would result in either p53 dependent apoptosis or 
cell cycle arrest due to p53 blockade. 
 
Figure  9. Simplified representation of the crosstalk between Erk and Akt; and the cell 
cycle and apoptosis. 
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      A direct consequence of the crosstalk is the generally disappointing 
single-targeted therapy against the different components developed based on 
traditional understanding of the means by which these pathways were thought to 
govern cell processes. The pathways were characterized as simple, linear and 
unidirectional. However, emerging studies have revealed that the two seldom act 
in isolation, but rather through multiple crosstalk and feedback interaction within 
a complex, well-coordinated network (Figure10).38 As such, it is apparent that 
perturbations targeting specific signaling molecules may have unexpected 
effects, and in some cases the compensatory pathways have been shown to 
mediate drug resistance.59 In view of this, a great deal of effort has been focused 
on experiments aimed at improving the understanding of the interplay and 
molecular mechanisms of the two pathways, which will in turn provides access to 
novel strategies with improved clinical outcome.  
Encouragingly, several studies indicate that simultaneous inhibition of the 
pathways may be required for optimal efficacy. Theoretically, the complete 
blockage of the pathways at upstream receptors may be valid, but could have 
deleterious effects and may result in significant normal cell toxicity. Alternatively, 
blocking a subset of downstream effector molecules would be a more pragmatic 
approach. Interestingly, there have been collaborations between large 
SKDUPDFHXWLFDO FRPSDQLHV )RU H[DPSOH WKH FRPELQDWLRQ RI 1RYDUWLV¶ 3,.
LQKLELWRU %.0 DQG *6.¶V 0(. LQKLELWRU *6. LQ SKDVH ,
development for triple negative breast cancer. Similarly, the combination of 
$VWUD=HQHFD¶V 0(. LQKLELWRU $=' DQG 0HUFN¶V $NW LQKLELWRU 0.
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undergoing phase I trials for locally advanced or metastatic solid tumors.26 
Evidently, a single compound targeting both pathways is a realistic therapeutic 
option with inherent advantages of increased patient compliance and reduced 
risk of drug resistance.  
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3. Rationale: Discovery and identification of lead dual-pathway inhibitor of 
the Raf/MEK/ERK and PI3K/AKT signaling pathways. 
3.1 Development of ERK1/2 inhibitor. ERK1/2 represents a near optimal target 
to develop such inhibitors given the following facts: (1) the important position of 
ERK1/2 in the Raf/MEK/ERK1/2 pathway that controls the distribution of signals 
from upstream; (2) the disclosure of the crystal structures of ERK2; and (3) The 
identification of the docking groove composed of a common docking (CD) 
domain and an ED domain on ERK2 and the validation of their roles in the 
control of docking interaction with substrate proteins. Taking advantage of a 
IDYRUDEOH VLWXDWLRQ WKH 6KDSLUR¶V JURXS LGHQWLILHG VHYHUDO VXFK LQKLELWRUV E\
computer-aided virtual screening of a small library of compounds (Fig. 10).60  
 
Figure 10: Putative substrate-specific ERK 1/ 2 inhibitors  
Among these structures, compound 76 represents an interesting chemical 
scaffold. Compound 76 inhibited the phosphorylation of the downstream 
substrate of ERK1/2, Rsk and Elk-1, in U937 cells with minimal effects on the 
phosphorylation of ERK1/2. In addition, small molecules containing the 
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thiazolidine-2,4-dione moiety, such as the anti-diabetic drug troglitazone, have 
been recently reported to have anti-cancer activities. Thus, these results 
demonstrated the potential of compound 76 as a new chemotype to develop 
substrate-specific ERK1/2 inhibitors. 60 
Due to the fact that compound 76 was discovered as a lead through 
screening, little information about the pharmacophore of compound 76 is known 
and there have been no reports of efforts to modify 76 to improve its bioactivity. 
In a previous study, we initiated preliminary structure-activity relationship (SAR) 
studies of compound 76 to define its pharmacophore and to search for more 
potent and selective substrate-specific ERK1/2 inhibitors. Immunoblot studies 
established that 1c showed improved activity compared to 76 (Fig. 13A).61  
 
C 
 
                                                 76 
D 
 
                                                  1c 
Figure 13: Effect of test compound on Rsk, ERK 1/2, Elk-1, MEK 1/2 and p38 
phosphorylation. A: Immunoblot results B: Quantification of Rsk-1 phosphorylation by 
densitometry C:  Compound 76 and D: Compound 1c. 
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3.2 Discovery of a lead dual-pathway inhibitor. In our effort to design and 
discover novel templates targeting the Raf/MEK/ERK and the PI3K/AKT signaling 
cascade, we have embarked on further characterization of our recently 
discovered lead ERK inhibitor, 1c. Preliminary structure±activity relationship 
(SAR) studies was initiated to define its pharmacophore. To facilitate the 
structure activity relationship the lead was again divided into three domains: a 
phenyl ring domain, a thiazolidinedione domain and an ethylamine domain. 
Compound 1 emerged as a novel chemotype with several features that may have 
contributed to its activity. These include the phenylpropylidene double bond as a 
Michael addition acceptor, the primary amine for ionic interaction and the 
aromatic ring for hydrophobic interaction.63 
The cell viability and proliferation effect of compound 1 was investigated 
using the [(3- (4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sul- 
fophenyl)-2H-tetrazolium] (MTS) assay and 3H thymidine respectively in U937 
cells. The known MEK inhibitor PD184352 was used as positive control. 
Compound 1 exhibited significant inhibition on U937 cell viability at higher 
concentrations (15, 20, and 25 PM) but not at concentration less than 10 PM 
(Figure 13C). Since the MTS assay only examines the metabolically healthy 
cells, but cannot distinguish whether the cells are actively dividing or quiescent, 
the [3H]- thymidine incorporation assay was used to investigate the actively 
dividing cells by detection of DNA synthesis. At 10 PM, 1 significantly inhibited 
the [3H]-thymidine incorporation, while PD184352 did not. At 30 PM, 1 almost 
completely inhibited [3H]-thymidine incorporation, and PD184352 also exhibited 
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significant inhibition at this concentration (Figure 13D). Taken together, these 
results may indicate that 1 may induce early apoptosis of U937 cells through 
inhibiting DNA synthesis at 10 PM but not affecting cell viability. 
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Figure  14.  Western blot analysis of compound 1 and its analogs in U937 cells a) Raf/ 
MEK/ ERK components b) PI3K components. Inhibition of cell proliferation using MTS 
assay (c) and [3H]-thymidine incorporation (d) in human leukemia U937 cells. 
 
To get insight into the signaling pathways that DUHSRVVLEO\LQYROYHGLQ¶V
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functional activities, Western blot analysis was then performed in U937 cells. As 
shown in Figure 14A, PD184352 significantly inhibited the phosphorylation of 
both ERK and its downstream substrate Rsk1 at as low as 3PM concentration. 
Compound 1 also significantly inhibited the phosphorylation of ERK and Rsk1 at 
10 PM and 30 PM concentrations, therefore being slightly less potent than 
PD184352 (Figure 14). However, when the p-MEK level was evaluated, it is 
notable that 1 induced dose dependent decrease the p-MEK level in U937 cells 
while treatment with PD184352 resulted in a dose-dependent increase in the p-
MEK levels, which is consistent with the reported negative feedback mechanism 
in the Raf/MEK/ERK pathway. Interestingly, 1 at 25 PM significantly suppressed 
p-Akt levels while the specific MEK inhibitor showed no inhibitory effects.  This 
might indicate that 1 targets either an upstream activator of MEK in the 
Raf/MEK/ERK signaling pathway or it inhibits MEK via a different mechanism.  
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4. Objective: Development of oxindole analogs as potential dual pathway 
inhibitors and anticancer agents. In order to develop novel chemotype of 
dual-pathway inhibitors as well as to develop a chemical template that would 
provide more flexibility for future structural modification, we intend to replace the 
TZD ring with an oxindole ring (Figure 15). The oxindole was identified as a 
more attractive replacement for the thiazolidinedione ring based on parallel 
study with the maleimide analog using the MTT assay. The design hypothesis 
was that both ring system would orient the critical structural features such as the 
ring system, the spacer and the ethylamine tail in a similar manner to that in the 
TZD analogs, and thereby retain the biological activity as dual-pathway inhibitors 
of the Raf/MEK/ERK and PI3K/Akt signaling pathways.  
In comparison to the thiazolidinedione lead, the oxindole analog showed 
improved potency (4-fold increase) while the maleimide analog showed a 
decrease in potency (10-fold decrease). This suggests that the aromatic ring 
system of the oxindole ring which is absent in the maleimide ring may contribute 
to the observed activity. The results were also consistent with the recognition of 
the oxindole template as a privileged template in drug discovery. In addition to 
the oxindole analog being 4-fold more potent than the lead compound 1, the 
oxindole ring would also provide greater flexibility to allow the introduction of 
various substituents, and thus facilitate comprehensive SAR studies for future 
investigation. 
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Figure 15: Thiazolidinedione lead and designed oxindole analogs.  
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4.1 Design of oxindole analogues. To obtain structural information about the 
features of compound  2 that are critical to the anticancer activity, compound 2 
was divided into the said three domains like compound 1, namely (1) phenyl ring 
domain; (2) ethylamine domain and (3)  oxindole domain. As shown in figure 15, 
compounds 2-6 were designed to highlight the role of the aromatic ring in 
biological activity. Particularly, it was examined if the replacement of the phenyl 
ring with cyclohexyl, adamantyl, cyclopropyl or nonyl groups would be tolerated 
or improve activity. Compounds 7-13 were designed to evaluate the influence of 
electrostatic and sterics of the substituent on the phenyl ring on the biological 
activity. The substitutions were made in 4-phenyl position and varied from high to 
moderate electron-donating and electron-withdrawing groups (Figure 15). 
The synthesis was initiated with the preparation of various aldehydes as 
shown in Scheme 1. The substituted benzaldehydes were converted to their 
Meldrum¶s acid derivatives followed by reduction and hydrosilylation to give the 
different aldehydes.  
43 
 
Scheme 1: a) Meldrum acid, piperidine, EtOH b) NaBH4, AcOH, CH2Cl2; c). PhSiH3, 
Et3N, THF c) DMSO, (COCl)2, Et3N, CH2Cl2, -78oC 
 
The synthesis 3-cyclohexylpropanal, 3-cyclopropylpropanal as well as 3-
adamantan-1-yl)propanal was achieved through the oxidation. While (3-
cyclohexylpropanal and 3-cyclopropylpropanol were commercial available, 3-
44 
adamantan-1-yl)propanal required synthesis. As shown in scheme 2, this 
synthesis started with the radical conjugate addition of bromoadamantane 25 to 
ethyl acrylate using nBu3SnH to afford the adamantyl ester 26. Reduction with 
lithium aluminum hydride (LAH) then yielded the primary alcohol 27. 3-
cyclohexylpropanol, 3-cyclopropylpropanol as well as 3-adamantan-1-yl)propanol 
were subsequently obtained by swern oxidation 
 
 
Scheme 2: a) nBu3SnH, AIBN, ethyl acrylate, toluene, rt b) LAH, THF, rt c) DMSO, 
ClCH2OCl, Et3N, CH2Cl2, -78oC 
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Scheme 3: a) DMSO, ClCH2OCl, Et3N, CH2Cl2, -78oC 
 
In retrospect, compound 36 was synthesized in a four-step reaction 
beginning with aniline. The N-substituted Boc analog of aniline was synthesized 
from the alkylation reactions with 2-bromoethylamine and carbamic acid tert-butyl 
ester. The secondary amine of compound of compound 34 was readily 
acetylated to the chloroacetanilide. With catalytic amounts of palladium acetate in 
combination with 2-(di-tert-butylphosphino)biphenyl as a ligand, and triethylamine 
as base, the chloroacetanilides was converted to oxindoles with high levels of 
regioselectivity. Knoevenagel condensation of the various aldehyde with 
compound 36, followed by the removal of Boc or tert-butyl ester group afforded 
compounds 2-13 (scheme 4). 
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Scheme 4: a) H2NCH2CH2Br, toluene, reflux; b) Boc2O, MeOH, rt  c) ClCH2OCl, CH2Cl2, 
0oC, d) Pd(OAc)2, L, Et3N, toluene, 80oC e) RCHO, piperidine, EtOH, reflux (f) Dioxane-
HCl, EtOAc 
 
The scheme employed to synthesized the oxindole analogues was 
carefully devised.  As a starting material, aniline has the advantage of being 
cheap and available. Another favorable feature of this synthetic route is the 
palladium catalyzed C-H functionalization. This step circumvent the need for high 
temperature as in the Wolff-Kishner reduction of isatin to oxindole, as well as the 
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combination of both high temperature and strongly acidic in Friedel-craft 
reasction.  Abrogating the need for harsh conditions, the palladium-catalysed 
synthesis of oxindole cyclization is highly compatible extending to even electron 
difficient aromatic systems. 
The maleimide analog 43 in the preliminary set of experiment was also 
synthesized. The condensation of the maleimide and hydrocinnamaldehyde was 
achieved by Wittig reaction through a phosphorane intermediate 40. The N-
alkylated product 42 was obtained by Mitsonubu reaction. 
 
 
Scheme   5: (a) PPh3, acetone, reflux; (b) RCHO, methanol, reflux; (c) 
BocNHCH2CH2OH, PPh3, DIAD; (d) Dioxane-HCl, EtOAc. 
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3. Discussion 
3.1 Anti-proliferative activity in human leukemia U937 cells. The activation of 
the Raf/MEK/ERK and PI3K/Akt signaling pathways has been shown to play 
multiple roles in the cell proliferation and apoptosis of hematopoietic cells 
including U937 cells. Accordingly, the U937 cells were employed for preliminary 
testing of the compounds. We first tested the anti-proliferative activity of the 
designed oxindole analogs. Notably, as shown in Table 1, all of the designed 
compounds exhibited anti-proliferative activity against the growth of U937 cells 
with micromolar or sub-micromolar potency. This also confirms that oxindole 
template can retain the anti-proliferative activity of these analogs, thus supporting 
our design rationale.  
Compared to lead compound 1, compound 2 in the oxindole series 
improved anti-proliferation activity (4-fold increase). While the cyclohexyl analog 
exhibited improved antiproliferation activity in comparison to compound 2, in the 
oxindole series, compound 3 exhibited comparable effects to compound 2, 
suggesting that sterics may not play a pivotal role since the phenyl ring is planar 
whereas the cyclohexyl group can flip between the chain, boat and other 
translational conformations. This notion was further supported by the fact that 4 
and 5 with the cyclopropyl ring and the adamantyl ring respectively showed 
comparable anti-proliferation potency with compound 2.  
Compounds 7 and 8 exhibited anti-proliferative activity with sub micro-
molar potency, the best two among the compound tested here. Combining the 
results from compound 2-6, this may indicate that the target protein may contain 
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a narrow binding pocket to interact with phenyl group through hydrophobic 
interactions. This hypothesis was further supported by the results of compounds 
9 and 10 with reduced potency in comparison to 7 and 8. As compound with 
electron-withdrawing substitutions on the phenyl ring (compounds 11-14) they 
also exhibited comparable potency to compound 2, suggesting mainly 
hydrophobic interactions with the phenyl ring. Interestingly, variation of the 
inhibitory effect on the U937 was most evident at 3 PM of drug concentration, 
which is around the average IC50 value for the series (Figure 17). Notably, 
compound 7 was observed to significantly inhibit cell growth at 3 PM  (73.5 % 
inhibition) while other compounds achieved the same inhibition at 10 PM. 
 
Figure 16: U937 cells were treated with compounds 2-13for 72 hours and the viability 
was analysed using the MTT assay 
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Table 1: Growth inhibition of U937 cells by compounds 2-13 (PM) 
 
A  
  
B  
  
C  
  
D  
  
  
Figure 17: Anti-proliferative effects of compounds on U937 cells assayed using MTT. 
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3.2 Western Blot Analysis of compounds 7 and 10. To confirm that the growth 
inhibition of U937 cells by these oxindole analogs were mediated through the 
inhibition of the Raf/MEK/ERK and PI3K/Akt signaling cascades. Compounds 7 
and 10 were selected for western blot analysis in U937 cells, as compound 7 was 
the most active one among the tested analogs and its comparison with 
compound 10 may shed some light on mechanistic information.  
 
Figure   18: U937 cells were treated with Compound 7 and 10 at the indicated 
concentrations for 24 hours. Lysate from culture was analyzed by primary antibodies. 
 
 As shown in Figure 18, both compounds consistently suppressed the 
expression of the critical components of these two signaling pathways, p-ERK 
and p-AKT, at concentration as low as 5 PM. Surprisingly, compound 10 
appeared to have a more significant effect on inhibition of p-ERK than compound 
7, while compound 7 is more potent than compound 10 in the anti-proliferation 
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assay of U937 cells. This may indicate that a more balanced inhibition on both 
signaling pathway is necessary to show optimal pharmacological outcome. As 
reflected by anti-proliferation here, the significant inhibition of one signaling 
pathway does not equal to the optimal cytotoxic effects, thus, further attesting to 
the rationale of designing dual-pathway inhibitors. Taken together, the results of 
the anti-proliferative assay and western blot indicate that signaling blockage and 
growth inhibition by these newly designed oxindole analogs in U937 cells are 
correlated.  
 
3.3 Apoptotic effects of compounds 7 and 10. As the Raf/MEK/ERK and 
PI3K/Akt signaling pathways have been demonstrated to play important roles in 
regulating apoptosis, the apoptotic effects of 7 and 10 were evaluated in U937 
cells using cytometry to obtain preliminary mechanistic data for the anti-
proliferative activity. As shown in Figure 19, both compounds significantly 
induced apoptotic effects on U937 cells after 24 hr treatment at as low as 5 M 
(63.9% and 21.7% for compound 7 and compound 10, respectively).  
Both compounds also induced significant apoptosis at 10 PM. 
Interestingly, compound 7 induced early apoptosis at both concentrations while 
compound 10 only induced late apoptotic effects in U937 cells under the 
experimental conditions. As discussed above, compound 7 and compound 10 
have different inhibitory effects on the Raf/MEK/ERK and PI3K/Akt signaling 
pathways as demonstrated by western blot results. This phenomenon might 
contribute to the distinct apoptotic effects since both signaling pathways can 
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regulate apoptosis through differential downstream substrates. This also does 
not rule out the possibility of the involvement of other off-targets that these two 
compounds might interact. Further studies are needed to get more information 
about the mechanism underlying the different apoptotic effects in U937 cells. 
 
Figure  19: Compounds 7 and 10 induced apoptosis in U937 cells. The U937 cells were 
treated for 24 hours with the drugs, after which they were stained with Annexin VI/ PI 
and analyzed by flow cytometry.  
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3.4 Conclusion In summary, the work presents the design and biological 
characterization of a series of oxindole compounds as novel dual-pathway 
inhibitors of the Raf/MEK/ERK and PI3K/AKT pathways. The MTT anti-
proliferative assay, western assay and apoptotic assay were employed to 
investigate biological activity in human leukemia U937 cells. All of the designed 
compounds exhibited anti-proliferative activity against the growth of U937 cells 
with micromolar or sub-micromolar potency. Western blot analysis correlated the 
anti-proliferative activity of the Raf/MEK/ERK and PI3K/Akt signaling pathways 
with suppression of critical pathway components. Lastly, the apoptotic assay 
shed some light one the preliminary mechanistic information. Taken together the 
results strongly support our design rationale by showing anti-proliferation, 
inhibitory effects of the signaling pathways, and apoptotic effects of these 
oxindole analogs.  The results also suggest the potential of the oxindole template 
as new lead compounds to develop newer generation of dual-pathway inhibitors 
of the Raf/MEK/ERK and PI3K/Akt.  
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5. Experimental 
*HQHUDO3URFHGXUHIRU3UHSDUDWLRQRIPHOGUXP¶VDFLGLQWHUPHGLDWHV: To a solution 
RI0HOGUXP¶VDFLGPPRODQGGURSVRISLSHULGLQHLQHWKDQRODU\ODOGHK\GH
was added. The resulting solution was stirred at room temperature overnight. 
The reaction mixture was filtered via Buckner filtration and washed with ethanol 
and methanol to obtain the pure intermediate. 
5-(3-(4-Methoxyphenyl)-methylene)-2,2-dimethyl-1,3-dioxane- 4,6-dione (15) 
1H NMR (300 MHz, CDCl3): 8.38 (s, 1H), 8.24-8.21 (d, J= 9.3 Hz, 2H), 6.99-6.97 
(d, J = 9.3 Hz, 2H), 3.91 (s, 3H), 1.79 (s, 6H). 
5-(3-(4-Ethoxyphenyl)-methylene)-2,2-dimethyl-1,3-dioxane- 4,6-dione (16) 
1H NMR (300 MHz, CDCl3): 8.37 (s, 1H), 8.23 (d, J = 9.3 Hz, 2H), 6.97-6.99-
6.55 (d, J = 9.3 Hz, 2H), 4.13-4.08 (q, J = 7.0 Hz, 2H), 1.78 (s, 6H), 1.26-1.23, (t, 
J=6.9Hz, 3H). 
5-(3-(4-Butoxyphenyl)-methylene)-2,2-dimethyl-1,3-dioxane- 4,6-dione (17) 
1H NMR (300 MHz, CDCl3): 8.37 (s, 1H), 8.22-8.21 (d, J = 9.3 Hz, 2H),6.97-6.95 
(d, J = 9.3 Hz, 2H), 4.09-4.06 (q, J =7.0 Hz, 2H), 1.78 (s, 6H), 1.55-1.45 (m, 2H), 
1.01-0.97 (t, J=7.4 Hz, 3H) 
5-(3-(4-Chlorophenyl)-methylene)-2,2-dimethyl-1,3- dioxane-4,6-dione (19) 
1H NMR (400 MHz, CDCl3): d 8.37 (s, 1H), 8.04-8.02 (d, J = 8.7 Hz, 2H), 7.47-
7.45 (d, J =8.7 Hz, 2H), 1.81 (s, 6H).  
5-(3-(4-Florophenyl)-methylene)-2,2-dimethyl-1,3- dioxane-4,6-dione (20) 
1H NMR (400 MHz, CDCl3): 8.39 (s, 1H), 8.19-8.15 (m, 2H), 7.17 (t, J=8.5 Hz, 
2H), 1.80 (s, 6H) 
5-(3-(4-Nitrophenyl)-methylene)-2,2-dimethyl-1,3-dioxane-4,6- dione (21) 
1H NMR (300 MHz, CDCl3): d 8.46 (s, 1H), 8.32-8.29 (d, J = 9.3 Hz, 2H), 
8.08.08-8.05 (d, J = 9.3 Hz, 2H), 1.84 (s, 6H). 
To a solution of 5-DU\OLGHQH0HOGUXP¶VDFLGGHULYDWLYHPPRODQGJODFLDODFHWLF
acid (4 mL) in dichloromethane at 0oC was added sodium borohydride (3.2 mmol) 
dropwise. The solution was dissolved in dichloromethane and washed with brine 
and water. The organic phase was extracted, dried over NaSO4. The monoakyl 
meldrum acid derivative  (1 mmol) was dissolved in THF.  Triethylamine (2 mmol) 
was then added followed by phenysilane (3 mmol). The resulting solution was 
stirred for 2 hrs at room temperature. Water was added to the solution and stirred 
for 15 mins. The reaction was dissolved in ether (50 mL) and washed with water 
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(2X50 mL) then with brine (50 mL). The organic layer was extracted. The 
separated ether phase was washed with brine and purified by flash 
chromatography (Hexane/ethyl acetate (EtOAc) 10/1) to give a colorless oil. 
5-(4-butoxybenzylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione (22) 
1H NMR (300 MHz, CDCl3): 8.37 (s, 1H), 8.23-8.21 (d, J=8.96, 2H), 6.97-6.95 (d, 
J=9.0 Hz, 2H), 4.09-4.06 (t, J=6.48 Hz, 2 H), 1.78 (s, 6H), 1.55-1.49 (q, J=7.2 Hz, 
2 H), 1.01-0.97 (t, J=7.4, 3 H), 1.76-1.74 (d, J=7.0 Hz, 2 H), 1.72 (s, 3H), 1.50-
1.44 (m, 5H)  
5-(4-butoxybenzyl)-2,2-dimethyl-1,3-dioxane-4,6-dione (23) 
1H NMR (300 MHz, CDCl3):  7.23-7.21 (d, J=8.64 Hz, 2H), 6.81-6.79 (d, J=8.64), 
3.93-3.90 (t, J=6.52 Hz, 2H), 3.73-3.70 (t, J=4.84 Hz, 1H), 3.44-3.42 (d, J=4.84 
Hz, 2H) 
3-butoxy-propionaldehyde (24)  
1H NMR (400 MHz, CDCl3): 9.81 (s,1 H), 7.10-7.08 (d, J=8.6 Hz), 6.83-6.81 (d, 
J=8.6 Hz, 2H), 3.95-3.92 (t, J=6.52, 2H), 2.92-2.88 (t, J=7.48, 2H), 2.76-2.72 (t, 
J=8.44, 2H), 1.77-1.71 (q, J=7.12 Hz, 2H), 1.55-1.43 (m, 3H), 0.99-0.95 (t, J=7.4 
Hz, 3H)  
DMSO (14.0 mmol) was added dropwise to a stirred solution of oxalyl chloride 
(5.0 mmol) in DCM (20.0 mL) at 78 C and the resulting reaction mixture was 
stirred for 20 min at this temperature. Then cyclopropyl-propanol or cyclopropyl-
propanol (4.0 mmol) was added dropwise and stirred for 1 h followed by the 
addition of Et3N (1.0 mL). The reaction was gradually brought to room 
temperature and H2O was added. The separated DCM phase was washed with 
brine and purified by flash chromatography (Hexane/ 1007 ethyl acetate 
(EtOAc): 10/1) to give a colorless oil. 
3-Cyclopropyl-propionaldehyde (31 a) 
1H NMR (400 MHz, CDCl3): d 9.80 (t, J = 1.8 Hz, 1H), 2.55-2.51 (m, 2H), 1.57-
1.51 (m, 2H), 0.71-0.67 (m, 1H), 0.48e0.43 (m, 2H), 0.07-0.04 (m, 2H). 
3-Cyclohexyl-propionaldehyde (31 b) 
1H NMR (400 MHz, CDCl3): d 9.77-9.76 (t, J = 1.9 Hz, 1H), 1011 2.45-2.41 (t, J 
= 7.5, 1.9 Hz, 2H), 1.71-1.55 (m, 5H), 1.51-1.49 (m, 2H), 1.26-1.11 (m, 4H), 0.93-
0.86 (m, 2H).  
Maleimide (1 mmol) and triphenylphosphine (1 mmol) in acetone (10 mL) was 
refluxed for 1 hour. The formed precipitates were collected by sucking filtration 
and washed with acetone. Yield, 65%.  
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3-(3-phenylpropylidene)pyrrolidine-2,5-dione (40) 
1H-NMR(400 MHz, CDCl3): į 7.63- 7.52 (m, 15 H), 3.03 (s, 2 H), 1.6536 (s, 2 H) 
Aromatic aldehyde (1 mmol), triphenylphosphoranylidene succinimide (1 mmol) 
and methanol were added a flask. The reaction mixture was stirred at reflux 
temperature for 1.5 hours. Yield, 45%.  
3-(3-phenylpropylidene)pyrrolidine-2,5-dione (41): 1H-NMR(400 MHz, 
CDCl3)į-7.15 (m, 5H), 6.86-6.81 (m, 1H), 3.01 (s, 2H), 2.83-2.80  (t, J=7.36, 
2H), 2.52-2.47 (q, J=7.44, 2H) 
A toluene solution of the Mitsonobu reagent, DIAD (1.5 mmol), was added 
dropwise to a THF solution of triphenylphosphine (1.5 mmol), maleimide 
derivative (1 mmol) and 2-tert-butoxycarbonylaminoethanol at room temperature. 
The reaction was stirred overnight. Solvent was removed under pressure and 
pure product was obtained by column chromatography. The Boc-protected 
compound  (1 mmol) was dissolved in ethylacetate (3 mL). Dioxane-HCl (1 
mmol) was added to the flask and the reaction was stirred for 2 hrs. Solid 
suspension was observed, the mixture was filtered and the collected solid 
washed with ethyl acetate and ether.Yield, 72%. 
(2-(2,5-dioxo-3-(3-phenylpropylidene)pyrrolidin-1-yl)ethanaminium chloride 
(43) 
1H-NMR(400 MHz, MeOD): į -7.17 (m, 5H), 6.83-6.78 (t, J=6.6 Hz, 1H), 
3.85-3.81 (t, J=7.6 Hz, 2H), 3.183-3.130 (m, 4H), 2.86- 2.81 (t, J=7.5, 2H), 2.60-
2.53 (q, J=7.8 Hz, 2H). 
Preparation of N-alkylated oxindole:   A mixture of 2-bromoethylamine 
hydrobromide (0.1 mmol) and analine (0.2 mmol) in 40 mL of toluene was heated 
at reflux for 16 hrs and then cooled. A solution of 60 mL of water and 20 mL of 
50% aqueous KOH was added, and the layers were separated. The aqueous 
solution was saturated with NaCl and extracted thrice with dichloromethane. The 
combined organic layers were washed with saturated NaCl solution, dried over 
anhydrous Na2SO4, filtered and evaporated to dryness. Column chromatography 
gave the pure product. Yield, 60%.   
N1-phenylethane-1,2-diamine (33):  
1+0+]0H2+į-7.08 (t, J=3.4 Hz, 2H), 6.67-6.60 (m, 3H), 3.23-3.20 
(t, J= 6.08 Hz, 2H), 2.90-2.87 (t, J=6.24 Hz, 2H). 
A solution of N-phenylethylenediamine and of di-t-butylcarbonate in methanol 
was stirred for 4 hrs and then concentrated by rotary evaporation to afford brown 
oil. Pure white solid was obtained from column chromatography.  
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tert-butyl (2-(phenylamino)ethyl)carbamate (34) 
1H NMR (400 MHz, CDCl3į-7.18 (m, 2H), 6.81-6.6 (m, 2H), 3.38-3.36 (d, 
J=7.6 Hz, 2H), 3.27-3.23 (t, J=8.0 Hz, 2H), 1.48 (s, 9H) 
A solution of SM, and triethylamine in dichloromethane was cooled to 0oC. 
Chloroacetyl chloride was added dropwise and the reaction was maintained at 
0oC with stirring. After 3 hrs, another portion of chloroacetyl chloride was added 
dropwise. After 30 min, the reaction was poured into ethyl acetate and washed 
with water, saturated aqueous ammonium chloride, saturated aqueous sodium 
bicarbonate solution and brine. The solution was dried over sodium sulfate, 
filtered and concentrated in vacuum giving brown oil, chloroacetamide.Yield, 
48%.  
tert-butyl (2-((chlorocarbonyl)(phenyl)amino)ethyl)carbamate (35) 
1H NMR (400 MHz, CDCl3 į -7.41 (m, 3H), 7.28-7.27 (d, J=6.6 Hz, 2H), 
3.87-3.83 (m, 4H), 3.35-3.34 (d, J=5.44 Hz, 2H), 1.4165 (s, 9H) 
An oven dried two-mouthed flask equipped with a magnetic stirrer was evacuated 
while hot and cooled under nitrogen. The tube was charged with palladium 
acetate (5%), 2-(di-tert-butylphosphino) biphenyl (Pd: ligand = 2:1), and 
chloroacetanilide (1 mmol). The tube was evacuated and backfilled with nitrogen. 
Anhydrous triethylamine (1.5 mmol) was added, followed by anhydrous 
anhydrous toluene (1.0 mL). The septum was replaced was replaced under a 
positive pressure of nitrogen, and the sealed tube was placed in an oil bath 
preheated to 80oC. After 16 hours, the reaction was allowed to cool to room 
temperature and was diluted with ethyl acetate (10 mL). The mixture was filtered 
through a plug of Celite and concentrated on a rotary evaporator. The crude 
material thus obtained was purified by silica gel chromatography to give product 
oxindole. Yield, 65%. 
tert-butyl (2-(2-oxoindolin-1-yl)ethyl)carbamate (36):  
1H NMR (400 MHz, CDCl3 į -7.21 (m, 2H), 7.04-7.00 (t, J=7.5 Hz, 1H), 
6.96-6.93 (d, 7.8 Hz,1H), 4.14-4.07 (d, J= 7.2 Hz, 2H), 3.86-3.82 (t, J= 8.0Hz, 
2H), 3.39-3.35 (q, J=5.7 Hz, 2H), 1.40( s, 9H). 
Various aldehydes (1.5 mmol) and piperidine (0.3 mmol) were added to a 
suspension of oxindole (1 mmol) in ethanol (15 mL). The solution was heated at 
80oC for 1.5 hours. The reaction was allowed to cool to room temperature. The 
precipitate was filtered, was in ethanol. The Boc-protected compound  (1 mmol) 
was dissolved in ethylacetate (3 mL). Dioxane-HCl (1 mmol) was added to the 
flask and the reaction was stirred for 2 hrs. Solid suspension was observed, the 
mixture was filtered and the collected solid washed with ethyl acetate and ether. 
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1-(2-aminoethyl)-3-(3-phenylpropylidene)indolin-2-one (2): 1H NMR (400 
0+]'062įV+-7.65 (d, J=7.52 Hz, 1H), 7.35- 7.2890 (m, 5H), 
7.23-7.20 (m, 2H), 7.10-7.06 (t, J=6.96 Hz, 1H), 6.90-6.86 (t, J=7.24 Hz, 1H), 
4.00-3.96 (t, J=6.48 Hz, 2H), 3.05- 2.99 (m, 4H), 2.95-2.91 (m, 2H). 
13 C NMR (100 MHz, DMSO): 167.0, 142.1, 140.7, 129.1, 128.4, 127.3, 126.1, 
123.6, 122.2, 121.6, 108.7, 37.0, 36.6, 33.7, 30.1 
 
1-(2-aminoethyl)-3-(3-cyclohexylpropylidene)indolin-2-one  (3): 1H NMR (400 
0+]'062įV+-7.63 (d, J=7.48, 1H), 7.35-7.31 (t, J=7.2 Hz, 
1H), 7.22-7.20 (d, J=7.72 Hz, 1H), 7.11-7.07 (t, J=8.16 Hz, 1H), 6.90-6.86 (t, 
J=7.76 Hz, 1H), 4.01-3.98 (t, J=6.48, 2H), 3.03-3.00 (m, 2H), 2.71-2.65 (q, J= 
7.64 Hz, 2H), 1.74-1.51 (m, 5H), 1.49-1.39 (q, J=7.56 Hz, 2H), 1.26-1.11 (m, 4H), 
0.97-0.88 (m, 2H) 
13 C NMR (100 MHz, DMSO): 167.1, 142.2, 142.2, 128.9, 128.4, 126.8, 123.4,  
122.2, 121.8, 108.7, 36.8, 36.7, 35.5, 32.6, 30.7, 26.1, 25.7 
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1-(2-aminoethyl)-3-(3-cyclopropylpropylidene)indolin-2-one (4) 1H NMR (400 
0+]0H2'į-7.33 (d, J= 6.88 Hz, 1H), 7.35-7.33 (t, J=6.84 Hz, 1H), 7.16-
7.07 (m, 3H), 4.11-4.08 (t, J=6.00 Hz, 2H), 3.27-3.24 (t, J=5.72 Hz, 3H) 2.88-2.83 
(q, J=7.44 Hz, 2H), 1.60-1.55 (q, J=7.16 Hz, 2H), 0.51-0.46 (m, 2H), 0.16-0.12 
(m, 2H) 
13 C NMR (100 MHz, DMSO): 170.5, 144.4, 143.1, 130.2, 128.5, 125.1, 124.0, 
123.7, 109.4, 39.3, 38.7, 34.8, 30.6, 11.7, 5.2. 
 
 
3-(3-((3r,5r,7r)-adamantan-1-yl)propylidene)-1-(2-aminoethyl)indolin-2-one 
(5)  
1+1050+]'062įV+-7.61 (d, J= 7.52 Hz, 1H), 7.35-
7.31 (t, J=7.72 Hz, 1H), 7.22-7.20 (d, J=7.84 Hz, 1H), 7.12-7.09 (t, J=7.52 Hz, 
1H), 6.91-6.87 (t J=7.84 Hz, 1H), 4.00-3.97 (t, J=6.56, 2H), 3.04-3.00 (q, J=5.44, 
2H), 2.65-2.59 (q, J=8.04 Hz, 2H), 1.99 (s, 3H), 1.71-1.60 (q, J=12.04 Hz, 6H), 
1.54 (s, 6H), 1.36-1.32 (m, 2H). 
13 C NMR (100 MHz, DMSO): 167.0, 157.1, 142.1, 140.9, 132.4, 129.3, 129.0, 
127.2, 123.5, 122.2, 121.6, 114.4, 114.3, 108.7, 67.0, 66.3, 37.0, 36.6, 32.8, 
30.8, 30.4, 18.7, 13.7. 
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1-(2-aminoethyl)-3-nonylideneindolin-2-one (6): 1H NMR (400 MHz, DMSO): 
įV+-7.65 (d, J= 7.56, 1H), 7.34-7.17 (t, J=7.68, 1H), 7.17-7.16 (d, 
J=7.8,  3H), 7.11-7.07 (t, J=7.56, 1H), 6.91-6.87 (t, J=7.80, 1H), 3.99-3.96 (t, 
J=6.32, 2H),2.71-2.65 (q, J=7.40, 2H), 1.61-1.57 (m, 2H), 1.39-1.26 (m, 11H), 
0.87-0.83 (t, J=6.60, 3H). 
13 C NMR (100 MHz, DMSO): 142.1, 129.0, 127.0, 123.5, 122.2, 121.7, 36.8, 
31.2, 28.8, 28.6, 28.0, 22.0, 13.9. 
 
 
1-(2-aminoethyl)-3-(3-(4-methoxyphenyl)propylidene)indolin-2-one (7) 1H 
NMR (400 MHz, '062įV+-7.64 (d, J= 7.48, 1H), 7.35-7.31 (t, 
J=7.72, 1H), 7.24-7.20 (t, J=8.48, 3H), 7.10-7.06 (t, J=7.60, 1H), 6.89-6.85 (m, 
3H), 4.00-3.96 (t, J=6.52, 2H), 3.01-2.95 (m, 4H), 2.88-2.85 (t, J=6.92, 2H), 2.51-
2.49 (m, 3H) 
13 C NMR (100 MHz, DMSO): 167.0, 157.7, 142.1, 141.9, 140.9, 140.6, 132.6, 
129.3, 129.2, 129.1, 128.7, 127.2, 123.5, 122.2, 121.8, 121.6, 119.4, 113.8, 
108.7, 108.4, 55.0, 37.0, 36.8, 36.8, 36.6, 33.4, 32.8, 30.4, 30.4, 29.3 
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1-(2-aminoethyl)-3-(3-(4-ethoxyphenyl)propylidene)indolin-2-one (8) 1H NMR 
 0+] '062 į  V + -7.64 (d, J= 7.48, 1H), 7.33-7.31 (t, 
J=7.72 Hz, 1H), 7.24-7.20 (m, 3H), 7.10-7.06 (t, J=7.60 Hz, 1H), 6.89-6.85 (m, 
3H), 4.00-3.96 (t, J=6.52, 2H), 4.00-3.96 (t, J=6.52 Hz, 3H), 3.01-2.95(m, 4H), 
2.88-2.85 (t, J=6.92 Hz, 2H), 2.51-2.49 (m, 3H) 
3C NMR (100 MHz, DMSO): 167.1, 142.1, 132.4, 129.3, 129.0, 127.2, 123.6, 
121.7, 114.2, 108.6, 62.9, 37.1, 36.8, 32.8, 30.4, 14.7 
 
 
1-(2-aminoethyl)-3-(3-(4-butoxyphenyl)propylidene)indolin-2-one (9) 1H NMR 
(400 MHz, DMSO): į V+-7.64 (d, J= 7.48 Hz, 1H), 7.35-7.31 (t, 
J=7.72 Hz, 1H), 7.22-7.16 (m, 3H), 7.08-7.07 (t, J=6.92 Hz, 1H), 6.89-6.84 (m, 
3H), 4.00-3.97 (t, J=6.56 Hz, 2H),3.94-3.91 (t, J=6.44 Hz, 3H), 3.03-2.95(m, 4H), 
2.87-2.84 (t, J=6.96, 2H),1.70-1.63 (m, 2H), 1.45-1.39 (m, 2H), 0.94-0.90 (t, 
J=7.36 Hz, 3H) 
13 C NMR (100 MHz, DMSO): 167.1, 142.9, 142.1, 128.9, 126.5, 123.3, 122.2, 
121.7, 108.7, 66.3, 108.7, 37.0, 36.7, 36.6, 36.5, 32.0, 28.0, 22.4 
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1-(2-aminoethyl)-3-(3-(4-(heptyloxy)phenyl)propylidene)indolin-2-one (10)  
1H 1050+]'062įV+-7.64 (d, J= 7.48 Hz, 1H), 7.35-
7.31 (t, J=7.72 Hz, 1H), 7.22-7.18 (m, 3H), 7.10-7.06 (t, J=7.56 Hz, 1H), 6.89-
6.84 (m, 3H), 3.99-3.95 (t, J=6.32, 2H), 3.93-3.90 (t, J=6.52 Hz, 3H), 3.02-2.95 
(m, 4H), 2.87-2.84 (t, J=7.04 Hz, 2H),1.72-1.65 (m, 2H), 1.43-1.17 (m, 8H), 0.88-
0.85 (t, J=6.64 Hz, 3H) 
3C NMR (100 MHz, DMSO): 167.0, 157.1, 142.1, 140.9, 132.4, 129.3, 129.0, 
127.2, 123.6, 122.2, 121.7, 114.4, 108.6, 37.0, 36.7, 32.8, 31.2, 30.4, 28.7, 28.7, 
28.4, 25.5, 22.0, 13.9. 
 
 
 
1-(2-aminoethyl)-3-(3-(4-fluorophenyl)propylidene)indolin-2-one (11): 1H 
1050+]0H2'į-7.64 (d, J=7.56, 1H), 7.35- 7.27 (m, 3H), 7.13-
6.97 (m, 5H), 7.10-7.06 (t, J=6.96 Hz, 1H), 6.90-6.86 (t, J=7.24 Hz, 1H), 4.09-
4.06 (t, J=5.88 Hz, 2H), 3.26- 3.23 (t, J=6.12 Hz, 2H), 3.08-3.03 (m, 2H), 2.99-
2.95 (m, 2H). 
13 C NMR (100 MHz, DMSO): 170.0, 164.2, 161.8, 143.1, 138.0, 131.2, 130.4, 
129.0, 125.0, 124.1, 123.5, 116.3, 116.1, 109.5, 39.3, 38.7, 34.6, 32.1 
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1-(2-aminoethyl)-3-(3-(4-chlorophenyl)propylidene)indolin-2-one (12) 1H 
1050+]'062įV+ 7.67-7.65 (d, J=7.52 Hz, 1H), 7.36- 7.32 
(m, 5H), 7.17-7.15 (d, J=7.80 Hz, 2H), 7.10-7.06 (t, J=6.96 Hz, 1H), 6.87-6.84 (t, 
J=7.04 Hz, 1H), 3.98-3.94 (t, J=6.28 Hz, 2H), 3.04- 2.99 (m, 4H), 2.95-2.91 (m, 
2H). 
13 C NMR (100 MHz, DMSO): 140.4, 139.8, 130.7, 129.1, 128.3, 127.4, 123.6, 
122.2, 121.6, 108.7, 37.1, 36.7, 33.0, 29.9 
 
 
1-(2-aminoethyl)-3-(3-(4-nitrophenyl)propylidene)indolin-2-one (13) 
 1+1050+]0H2'į-8.74 (d, J=7.48 Hz, 3H), 7.67-7.65 (d, J=7.52 
Hz, 1H), 7.35- 7.2890 (m, 5H), 7.23-7.20 (m, 2H), 7.10-7.06 (t, J=6.96 Hz, 1H), 
6.90-6.86 (t, J=7.24 Hz, 1H), 4.00-3.96 (t, J=6.48 Hz, 2H), 3.05- 2.99 (m, 4H), 
2.95-2.91 (m, 2H). 
13 &1050+]'062į
124.2, 123.2, 115.6, 109.5, 37.9, 38.7, 26.6, 32.1 
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5.1 Cell Proliferative Assay  
The technique is based on the tetrazolium ring of 3-[4, 5-dimethylthiazol-2-
yl]-2, 5-diphenyltetrazolium (MTT) that is cleaved by mitochondria reductase in 
living cells to produce a purple formazan. The purple formazan dissolved in 
DMSO is quantified at 540 nm. The assay reflects the number of viable cells, 
since reduction can only be stimulated by activated mitochondrial enzyme. The 
U937 cells were seeded at a density of 2 X105, and 100 PL of cells were added 
per well in a 96-well plate with a multi-channel pipette. The cells were treated 
with 100 PL of active compounds at the concentration: 0, 1, 3, 10 and 30 PL. 10 
PL of 5mg/ mL of (3-(4,5-Dimethylthiazol -2-yl)-2,5-diphenyltetrazolium 
bromide was added to each well and allowed to incubate at 37oC in a fully 
humidified atmosphere containing 5% CO2. After which 170 PL of medium 
was extracted from each well, and 100 PL DMSO was added and mixed 
thoroughly to ensure homogeneity. The intracellular soluble formazan produced 
by the cellular reduction of the MTT was determined by recording the absorbance 
of each 96-well plate using the automatic microlplate photometer (Flexstation3, 
Molecular Device, USA) at wavelength 570 nm. The values were expressed as 
percentage relative to those obtained in untreated controls. The IC50 was 
determined by constructing a dose-response curve.  
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5.2 Western Blot Assay 
 Cells (5 X105/mL) were pretreated with compounds for 1 h, prior to being 
lysed by sonication in 1x sample buffer [62.5 mM Tris base (pH 6.8), 2% SDS, 50 
mM DTT, 10% glycerol, 0.1% bromphenol  blue, and 5 mg/mL each chymostatin, 
leupeptin, aprotinin, pepstatin, and soybean trypsin inhibitor] and boiled for 5 min. 
For analysis of phosphoproteins, 1 mM of sodium orthovanadate and sodium 
pyrophosphate was added to the sample buffer. Protein samples were collected 
from the supernatant after centrifugation of the samples at 12,800 g for 5 min, 
and protein was quantified using Coomassie Protein Assay Reagent. 
 Equal amounts of protein (30.0 mg) were separated by SDS-PAGE on 4-
10% tris/glycine gel (Bio-Rad) and electrotransferred onto a PVDF membrane 
(Bio-Rad). For blotting phospho-proteins, no SDS was included in the transfer 
buffer. The blots were blocked with 5% milk in TBS-Tween 20 (0.1%) at 25oC for 
1 h and probed with the appropriate dilution of primary antibody overnight at 4 
oC.  The blots were washed twice in TBS-Tween 20 for 15 min then incubated 
with a 1:2000 dilution of horseradish peroxidase conjugated secondary antibody 
in 5% milk/PBS-Tween 20 at 25oC for 1 h. After washing twice in TBS-Tween 20 
for 15 min, the proteins were visualized by Western Blot Chemiluminescence 
Reagent. The primary antibodies used: Phospho-p44/42 MAPK (Thr202/Tyr204) 
antibody (1:1000, rabbit polyclonal, p44/42 MAPK antibody (1:1000, rabbit 
polyclonal), phospho-MEK1/2 (1:1000, rabbit polyclonal), MEK1/2 (1:1000, rabbit 
polyclonal), phospho-Akt(Ser473) (1:1000, rabbit polyclonal),(1:1000,rabbit 
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polyclonal), Akt1/2/3 (H-136) (1:1000, rabbit polyclonal). 
5.3 Apoptosis assay  
 After treatment with compounds at indicated concentrations for 24 hours, 
cells were washed twice with cold PBS and then suspended in 1x binding 
buffer (10 mM HEPES [N-2-hydroxyethylpiperazine-N- 
ethanesulfonicacid]/NaOH, pH 7.4, 140 mM NaOH, 2.5 mM CaCl2). The 
cells were incubated with annexin V fluorescein isothiocyanate (FITC) and 
5mg/mL propidium iodide (PI), and incubated for 15 min at room temperature in 
the dark per the manufacturer¶s  instructions. The samples were analyzed by 
flow cytometry using a Becton Dickinson FACScan within 1 h to determine the 
percentage of cells displaying annexin V staining (early apoptosis) or both 
annexin V and PI staining (late apoptosis). 
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